

ONCOLOGY PORTFOLIO - Approved Products & Pipeline

INN /Compound	Class	Target & Modality	Indication or Disease	Discovery	Preclinical	Phase I	Phase II	Phase III	In Registration	Approved*
Vinorelbine	Chemotherapy	Vinca Alkaloid 	Advanced BREAST CANCER as monotherapy or in combination with other agents	[Progress bar]						
		Vinca Alkaloid 	Advanced NSCLC as monotherapy or in combination with other chemotherapies	[Progress bar]						
		Vinca Alkaloid 	Adjuvant treatment of NSCLC in combination with platinum-based chemotherapy	[Progress bar]						
Vinflunine	Chemotherapy	Vinca Alkaloid 	Advanced or metastatic transitional-cell carcinoma of the UROTHELIAL tract	[Progress bar]						
Neratinib¹	Targeted therapy	Pan-HER inhibitor 	HER2 amplified / overexpressed / HR+ early BREAST CANCER (extended adjuvant post trastuzumab based therapy)	[Progress bar]						
Tabelecleucel²	Cell therapy	Allogeneic T-cell immunotherapy 	Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV + PTLD)	[Progress bar]						
Encorafenib³ / Binimetinib⁴ (± other agents)	Targeted therapy	BRAF inhibitor + MEK inhibitor 	Unresectable or metastatic BRAF^{V600}-mutant MELANOMA	[Progress bar]						
		BRAF inhibitor 	Metastatic BRAF^{V600E}-mutant CRC after prior systemic therapy	[Progress bar]						
		BRAF inhibitor + MEK inhibitor 	Metastatic BRAF^{V600E}-mutant NSCLC⁵	[Progress bar]						
		BRAF inhibitor + MEK inhibitor 	Metastatic BRAF^{V600E}-mutant NSCLC in Chinese population - OCEAN study	[Progress bar]						
		BRAF inhibitor 	Previously untreated metastatic BRAF^{V600E}-mutant CRC⁶ - ANCHOR CRC study	[Progress bar]						
		BRAF inhibitor 	Previously treated metastatic BRAF^{V600E}-mutant CRC in Chinese population - NAUTICAL study	[Progress bar]						
Exarafenib⁷	Targeted therapy	Pan-RAF small molecule inhibitor 	NRAS mutant MELANOMA and other BRAF / NRAS mutant solid tumors	[Progress bar]						
PFL-721/STX-721⁸	Targeted therapy	Mutant-selective EGFR-exon20 small molecule inhibitor 	NSCLC with EGFR exon 20 insertion mutation	[Progress bar]						
PFL-241/STX-241⁸	Targeted therapy	Mutant-selective 4 th generation EGFR small molecule inhibitor 	NSCLC with EGFR exon 19/21 + C797S mutations	[Progress bar]						
PFL-002/VERT-002⁹	Targeted therapy	Anti-cMET antibody degrader 	NSCLC / solid tumors with mutations or amplification of MET	[Progress bar]						
Not-disclosed¹⁰	Targeted therapy	Multiple targets 	ONCOLOGY	[Progress bar]						

*Approved at least by EMA. Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation).

1.Commercialized in partnership with Puma Biotechnology. 2.Commercialized in partnership with Atara Biotherapeutics. 3.Encorafenib + cetuximab is approved for **BRAF^{V600E}-mutant mCRC**, after prior systemic therapy. Encorafenib + binimetinib is approved for unresectable or metastatic **BRAF**-mutant melanoma, in adult patients. 4.Developed and launched in partnership with Array Biopharma (partnered with Pfizer since 2020). 5.Clinical development under Pfizer sponsorship. 6.ANCHOR CRC study status: completed. 7.Originated by Kinnate Biopharma Inc. Investigational Pan-RAF inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories. 8.Co-development in partnership with Scorpion Therapeutics Inc., Boston, USA. The sponsor of these studies could be Pierre Fabre Medical Care or Scorpion Therapeutics Inc. 9.Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories. 10.Discovery partnership with Vernalis Ltd.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov